1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Multimodal AI to Accelerate Precision Medicine for Type 1 Diabetes (U01- Clinical Trials Not Allowed) is sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) - NIH. This forecast opportunity aims to combine multimodal human pancreas and clinical datasets to better understand how biological processes interact as Type 1 Diabetes (T1D) develops and progresses.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Opportunity Listing - Multimodal AI to Accelerate Precision Medicine for Type 1 Diabetes (U01- Clinical Trials Not Allowed) Multimodal AI to Accelerate Precision Medicine for Type 1 Diabetes (U01- Clinical Trials Not Allowed) Agency: National Institutes of Health Assistance Listings: 93. 847 -- Diabetes, Digestive, and Kidney Diseases Extramural Research Last Updated: August 20, 2026 View version history on Grants.
gov Type 1 diabetes (T1D) is a complex disease involving interactions among many different cell types, tissues, organs and biological processes. Genetics, the environment, and lifestyle all play a role in disease development and progression.
Over the past two decades, the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) has supported major T1D research consortia covering basic, translational, and clinical research. Each consortium has focused on different aspects of T1D, such as specific organs, stages of disease or clinical outcomes.
Together, these consortia have collected large longitudinal and multimodal datasets using standardized protocols and coordinated studies. While individual consortia have improved our understanding of specific areas, combining their work offers a rare opportunity to see how different biological processes interact to drive T1D development and progression.
This integrated view can answer fundamental questions about T1D biology that cannot be answered using individual datasets or studies alone. Recent advances in artificial intelligence (AI) now make it possible to integrate these complementary datasets and study T1D across various tissues, disease stages, and biological levels.
Building on these resources, NIDDK will support a coordinated, milestone-driven research project to answer fundamental questions about T1D biology and accelerate the development of personalized medicine. The project will combine multimodal human pancreas and clinical datasets to better understand how biological processes interact as T1D develops and progresses.
The research will generate new insights into T1D biology, help us understand the different forms and stages of T1D, identify biomarkers, and inform new approaches for disease prevention, intervention, and treatment. To support the research, the project will develop and test advanced multimodal AI models. It will also develop AI-enabled research workflows, new methods to integrate data, and privacy-preserving synthetic datasets.
For-profit organizations other than small businesses Other Native American tribal organizations Nonprofits non-higher education with 501(c)(3) Nonprofits non-higher education without 501(c)(3) Public and Indian housing authorities City or township governments Special district governments Federally recognized Native American tribal governments Public and state institutions of higher education Private institutions of higher education Independent school districts Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).
Grantor contact information Division of Diabetes, Endocrinology and Metabolic Diseases No documents are currently available.
Link to additional information Estimated Application Due Date : Estimated Due Date Description : Estimated Project Start Date : Funding opportunity number : Cost sharing or matching requirement : Funding instrument type : Opportunity Category Explanation : Category of Funding Activity : Your account requires additional identity verification.
According to the current listing, eligibility includes: Not specified in forecast; typically includes research institutions and other organizations. Confirm the full requirements in the official notice before applying.
Multimodal AI to Accelerate Precision Medicine for Type 1 Diabetes (U01- Clinical Trials Not Allowed) is funded by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) - NIH. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Energy efficient urban and sub-urban public transport, complemented by shared mobility is sponsored by European Commission — Horizon Europe. Expected Outcome: This topic aims at supporting activities that are enabling or contributing to the Climate-Neutral and Smart Cities Mission by accelerating the transition towards climate neutrality in cities. To this end, project results are expected to contribute to all of the following expected outcomes: Cities involved in this action advance in achieving their climate neutrality targets, reducing greenhouse gas and air pollutant emissions by improving energy efficiency in urban and sub-urban public transport systems , complemented by urban mobility service car fleets – taxis, ride-hailing, car sharing and other active and shared mobility services . Comprehensive inventory and assessment of existing instruments and measures to foster electrification and attractiveness of urban and sub-urban public transport systems , urban mobility service car fleets and shared mobility, accompanied by targeted guidance for responsible authorities, operators and providers through integration of measures to improve energy efficiency in public transport and new shared mobility services. Upscaling of innovative and sustainable integrated mobility solutions , identifying gaps and shortcomings in existing systems and exchanging of best practices in the pilot sites involved in the action leading to a state-of-the-art of electrification and attractiveness of urban and suburban public transport with complementary urban mobility service car fleets and other active and shared mobility solutions . Enhanced assessment tools to quantify the direct benefits and associated co-benefits of decarbonised urban mobility service car fleets and of new shared mobility solutions complementary to public transport (including evaluation of impacts on modal shift, increased intermodal mobility and diverse user needs), the trade-off analysis between different solution and the recommendation of the most suitable implementation strategies, thereby helping to attract public investments. Further progress towards achieving the targets set by relevant EU strategies and policies such as the Zero Pollution Action Plan [1] , the Sustainable and Smart Mobility Strategy [2] , the new EU Urban Mobility Framework [3] , the Decarbonise Corporate Fleets Communication [4] and the Energy Efficiency Directive [5] . Scope: Public transport is firmly at the centre of sustainable urban mobility policies at EU level and across Member States, in complementarity with active mobility and shared mobility services. However more needs to be done to make sure that urban and suburban public passenger transport, including coaches, and urban mobility service car fleets are energy efficient and attractive , contributing to climate neutrality targets as well as to cleaner and healthier urban and sub-urban environments. In addition, an optimal integration of public transport with other/new shared mobility services can increase its uptake by offering services that are complementary, offering coherent solutions allowing interconnection between mass transit and “last-mile” solutions. Designing urban and sub-urban systems that are energy-efficient and attractive and are tailored for complementary mobility options requires different thinking: e.g. new approaches to integrated urban planning; changes to or upgrades of infrastructure and redistribution of public space; better use of data and technology solutions to enable effective multimodality, including leveraging AI solutions; targeted local policies to promote and integrate different mobility options, to increase connectivity especially in peri-urban, rural, and underserved areas throughout the city, extending beyond the city centre. The objective of this topic is to explore and test solutions to increase energy-efficiency and attractiveness of urban and sub-urban public transport, urban mobility service car fleets, and other active and shared mobility solutions, in the pilot sites involved in the proposals, including by facilitating exchange of experienc Programme areas: Horizon Europe (HORIZON), Global Challenges and European Industrial Competitiveness, Climate, Energy and Mobility Keywords: Climate change mitigation, Decarbonisation, Mobility and transportation, Mobility management, Sustainable transport, Transport & Mobility, SSH (Social Sciences and Humanities), shared mobility, sustainable transport, urban and sub-urban public transport
Microsoft Research's global academic research program providing Azure AI compute credits and access to cutting-edge foundation models for research advancing AI safety, human-AI interaction, and scientific discovery. The program operates through periodic Calls for Proposals, workshops, and conferences. Focus areas include AI safety and responsibility (robustness, transparency, evaluation methods), human-AI interaction (trust, creativity, productivity, reducing digital divides), and scientific discovery (knowledge discovery, hypothesis generation, multimodal data generation). The program is evolving into the Agentic AI Research and Innovation (AARI) initiative focusing on intelligent agent systems.
JARVIS is a Horizon Europe-funded project accelerating the adoption of AI-powered human-robot collaboration (HRC) in European manufacturing. The project runs multiple open calls for SMEs and startups to develop and pilot AI-driven robotics solutions. The Co-development Track (Open Call 2) provides up to €100,000 per project to enhance the JARVIS framework by developing new modular human-robot interaction technologies, validating advanced collaborative robotics components up to TRL6, and accelerating their uptake in real industrial environments. The Technology Adopters Pilot Track offers up to €130,000 per project for 10-month pilots addressing specific human-robot interaction challenges. All funding is equity-free. Successful consortia also gain access to the JARVIS ecosystem of technology providers, end-users, and research experts. Proposals must address challenges centered on human-robot interaction and infrastructure inspection using AI-driven multimodal interaction for advanced collaborative robotics applications.
PA-27-037 consolidates the Predoctoral to Postdoctoral Transition Award into a single parent announcement across 20 NIH components, with the next deadline December 8, 2026. The eligibility gate is not the science — it is a mandatory change of institution and mentor between the F99 and K00 phases.
Read articleA draft executive order would have put OMB Director Russell Vought on a commission with final say over NIH awards after peer review. Sen. Collins killed it by pointing at a provision Congress already passed. Here is what the episode teaches applicants about the December 11 cliff.
Read articlePA-27-034, PA-27-035 and PA-27-036 replace the institute-specific R25 announcements that research education programs have been built around for a decade. NCI, NIDA and NIGMS have already expired theirs early. Here is what the consolidation actually changes: an 8% indirect cost ceiling, a US-citizens-and-permanent-residents participant rule, a cooperative agreement variant that only exists on one of the three, and no clinical-trial-allowed companion anywhere.
Read article